Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2017 Mar-2016 Mar-2015 Mar-2014
Growth matrix (%)        
Net interest income (80) 24 306 (80)
Total op income (78) 18 331 (83)
Op profit (pre-provision) (93) 2,342 (99) 23,664
Net profit (95) 2,065 (98) 32,359
Advances (3.20) (14) (12) (5.80)
Borrowings (100) 1,224 133 (98)
Total assets (1.50) (24) (0.90) (49)
Profitability Ratios (%)        
NIM -- -- -- --
Non-int inc/Total inc 10 0.94 5.67 0.01
Return on Avg Equity (2.60) (38) (1.50) (58)
Return on Avg Assets (2.30) (37) (1.50) (55)
Per share ratios ()        
EPS -- -- -- --
Adj.BVPS -- -- -- --
DPS -- -- -- --
Other key ratios (%)        
Loans/Borrowings -- 636 9,743 25,867
Cost/Income 8.27 821 1.94 4,480
CAR -- -- -- --
Tier-I capital -- -- -- --
Gross NPLs/Loans -- -- -- --
Prov/Avg loans -- -- -- --
Net NPLs/Net loans -- -- -- --
Tax rate -- -- (0.50) --
Dividend yield -- -- -- --
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2017 Mar-2016 Mar-2015 Mar-2014
Interest income 0.08 0.40 0.32 0.08
Interest expense -- -- -- --
Net interest income 0.08 0.40 0.32 0.08
Non-interest income 0.01 -- 0.02 --
Total op income 0.09 0.40 0.34 0.08
Total op expenses (0.30) (4) (0.50) (25)
Op profit (pre-prov) (0.20) (3.60) (0.10) (25)
Provisions (0.30) (6.90) (0.10) (1.70)
Exceptionals -- -- -- --
Profit before tax (0.60) (10) (0.30) (27)
Taxes -- -- (0.20) 0.02
Net profit (0.60) (10) (0.50) (27)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2019 Mar-2018 Mar-2017 Mar-2016
Equity Capital 214 214 214 214
Reserves (199) (195) (193) (192)
Net worth 15 19.40 21.50 22.10
Long-term borrowings -- -- -- --
Other Long-term liabilities 2.82 2.79 2.78 --
Long term provisions -- -- -- --
Total Non-current liabilities 2.82 2.79 2.78 --
Short Term Borrowings -- -- -- --
Trade payables -- -- -- --
Other current liabilities -- -- -- 2.78
Short term provisions -- -- -- --
Total Current liabilities -- -- -- 2.78
Total Equities and Liabilities 17.80 22.20 24.30 24.90
Fixed Assets -- -- -- --
Non-current investments 2.10 6.32 7.16 7
Deferred tax assets (Net) -- -- -- --
Long-term loans and advances 15.70 15.90 17.10 --
Other non-current assets -- -- 0.03 --
Total Non-current assets 17.80 22.20 24.30 7
Current investments -- -- -- --
Trade receivables -- -- -- --
Cash and cash equivalents -- 0.01 0.02 0.02
Short-term loans and advances -- -- -- 17.70
Other current assets -- -- -- 0.19
Total Current assets -- 0.01 0.02 17.90
Total Assets 17.80 22.20 24.30 24.90
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Jun-2019 Mar-2019 Dec-2018 Sep-2018
Gross Sales -- -- -- --
Excise Duty -- -- -- --
Net Sales -- -- -- --
Other Operating Income -- -- -- --
Other Income -- -- -- --
Total Income -- -- -- --
Total Expenditure ** 0.02 0.07 0.04 0.06
PBIDT -- (0.10) -- (0.10)
Interest -- -- -- --
PBDT -- (0.10) -- (0.10)
Depreciation -- -- -- --
Tax -- -- -- --
Fringe Benefit Tax -- -- -- --
Deferred Tax -- -- -- --
Reported Profit After Tax -- (0.10) -- (0.10)
Extra-ordinary Items -- -- -- --
Adjusted Profit After Extra-ordinary item -- (0.10) -- (0.10)
EPS (Unit Curr.) -- -- -- --
EPS (Adj) (Unit Curr.) -- -- -- --
Calculated EPS (Unit Curr.) -- -- -- --
Calculated EPS (Adj) (Unit Curr.)  -- -- -- --
Calculated EPS (Ann.) (Unit Curr.) -- -- -- --
Calculated EPS (Adj) (Ann.) (Unit Curr.)  -- -- -- --
Book Value (Unit Curr.) -- -- -- --
Dividend (%) -- -- -- --
Equity 214 214 214 214
Reserve & Surplus -- -- -- --
Face Value 10 10 10 10
Public Shareholding (No Of.Shares)  116,748,131 116,748,131 116,748,131 116,748,131
Public Shareholding (% in Equity)  54.50 54.50 54.50 54.50
Pledged/Encumbered - No. of Shares -- -- -- --
Pledged/Encumbered - % in Total Promoters Holding -- -- -- --
Pledged/Encumbered - % in Total Equity -- -- -- --
Non Encumbered - No. of Shares 97,508,369 97,508,369 97,508,369 97,508,369
Non Encumbered - % in Total Promoters Holding 100 100 100 100
Non Encumbered - % in Total Equity 45.50 45.50 45.50 45.50
PBIDTM(%) -- -- -- --
PBDTM(%) -- -- -- --
PATM(%) -- -- -- --